Conditionally replicative adenovirus as a therapy for malignant peripheral nerve sheath tumors

• Published in: Molecular therapy. Oncology Vol. 32; no. 2; p. 200783
• Main Authors: Nikrad, Julia A, Galvin, Robert T, Sheehy, Mackenzie M, Novacek, Ethan L, Jacobsen, Kari L, Corbière, Stanislas M A S, Beckmann, Pauline J, Jubenville, Tyler A, Yamamoto, Masato, Largaespada, David A
• Format: Journal Article
• Language: English
• Published: United States 20.06.2024
• Subjects: cyclooxygenase 2 (COX2); oncolytic adenovirus; conditionally replicative adenovirus (CRAd); neurofibromatosis type 1 (NF1); MT: Regular Issue; malignant peripheral nerve sheath tumor (MPNST)
• ISSN: 2950-3299
• DOI: 10.1016/j.omton.2024.200783

Oncolytic adenoviruses (Ads) stand out as a promising strategy for the targeted infection and lysis of tumor cells, with well-established clinical utility across various malignancies. This study delves into the therapeutic potential of oncolytic Ads in the context of neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNSTs). Specifically, we evaluate conditionally replicative adenoviruses (CRAds) driven by the cyclooxygenase 2 (COX2) promoter, as selective agents against MPNSTs, demonstrating their preferential targeting of MPNST cells compared with non-malignant Schwann cell control. COX2-driven CRAds, particularly those with modified fiber-knobs exhibit superior binding affinity toward MPNST cells and demonstrate efficient and preferential replication and lysis of MPNST cells, with minimal impact on non-malignant control cells. experiments involving intratumoral CRAd injections in immunocompromised mice with human MPNST xenografts significantly extend survival and reduce tumor growth rate compared with controls. Moreover, in immunocompetent mouse models with MPNST-like allografts, CRAd injections induce a robust infiltration of CD8+ T cells into the tumor microenvironment (TME), indicating the potential to promote a pro-inflammatory response. These findings underscore oncolytic Ads as promising, selective, and minimally toxic agents for MPNST therapy, warranting further exploration.